266 related articles for article (PubMed ID: 28646488)
41. A truncated derivative of FGFR1 kinase cooperates with FLT3 and KIT to transform hematopoietic stem cells in syndromic and de novo AML.
Cai B; Liu Y; Chong Y; Mori SF; Matsunaga A; Zhang H; Fang X; Chang CS; Cowell JK; Hu T
Mol Cancer; 2022 Jul; 21(1):156. PubMed ID: 35906694
[TBL] [Abstract][Full Text] [Related]
42. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
Quintanal-Villalonga Á; Ferrer I; Guruceaga E; Cirauqui C; Marrugal Á; Ojeda L; García S; Zugazagoitia J; Muñoz-Galván S; Lopez-Rios F; Montuenga L; Vicent S; Molina-Pinelo S; Carnero A; Paz-Ares L
EBioMedicine; 2020 Mar; 53():102683. PubMed ID: 32114392
[TBL] [Abstract][Full Text] [Related]
43. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.
Zhang L; Nomie K; Zhang H; Bell T; Pham L; Kadri S; Segal J; Li S; Zhou S; Santos D; Richard S; Sharma S; Chen W; Oriabure O; Liu Y; Huang S; Guo H; Chen Z; Tao W; Li C; Wang J; Fang B; Wang J; Li L; Badillo M; Ahmed M; Thirumurthi S; Huang SY; Shao Y; Lam L; Yi Q; Wang YL; Wang M
Clin Cancer Res; 2017 Aug; 23(15):4212-4223. PubMed ID: 28348046
[No Abstract] [Full Text] [Related]
44. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
Hanker AB; Garrett JT; Estrada MV; Moore PD; Ericsson PG; Koch JP; Langley E; Singh S; Kim PS; Frampton GM; Sanford E; Owens P; Becker J; Groseclose MR; Castellino S; Joensuu H; Huober J; Brase JC; Majjaj S; Brohée S; Venet D; Brown D; Baselga J; Piccart M; Sotiriou C; Arteaga CL
Clin Cancer Res; 2017 Aug; 23(15):4323-4334. PubMed ID: 28381415
[No Abstract] [Full Text] [Related]
45. Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.
Chudasama P; Renner M; Straub M; Mughal SS; Hutter B; Kosaloglu Z; Schweßinger R; Scheffler M; Alldinger I; Schimmack S; Persigehl T; Kobe C; Jäger D; von Kalle C; Schirmacher P; Beckhaus MK; Wolf S; Heining C; Gröschel S; Wolf J; Brors B; Weichert W; Glimm H; Scholl C; Mechtersheimer G; Specht K; Fröhling S
Clin Cancer Res; 2017 Feb; 23(4):962-973. PubMed ID: 27535980
[No Abstract] [Full Text] [Related]
46. Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease.
Ren M; Cowell JK
Blood; 2011 Jun; 117(25):6837-47. PubMed ID: 21527531
[TBL] [Abstract][Full Text] [Related]
47. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
48. AZD-4547 exerts potent cytostatic and cytotoxic activities against fibroblast growth factor receptor (FGFR)-expressing colorectal cancer cells.
Yao TJ; Zhu JH; Peng DF; Cui Z; Zhang C; Lu PH
Tumour Biol; 2015 Jul; 36(7):5641-8. PubMed ID: 25691251
[TBL] [Abstract][Full Text] [Related]
49. Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.
Lindblad O; Cordero E; Puissant A; Macaulay L; Ramos A; Kabir NN; Sun J; Vallon-Christersson J; Haraldsson K; Hemann MT; Borg Å; Levander F; Stegmaier K; Pietras K; Rönnstrand L; Kazi JU
Oncogene; 2016 Sep; 35(39):5119-31. PubMed ID: 26999641
[TBL] [Abstract][Full Text] [Related]
50. Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR‑FGFR1 fusion.
Qiu XH; Li F; Cao HQ; Shao JJ; Mei JG; Li HQ; Zhai YP
Mol Med Rep; 2017 Mar; 15(3):1024-1030. PubMed ID: 28138694
[TBL] [Abstract][Full Text] [Related]
51. DNA methyltransferase 1-mediated CpG methylation of the miR-150-5p promoter contributes to fibroblast growth factor receptor 1-driven leukemogenesis.
Hu T; Chong Y; Cai B; Liu Y; Lu S; Cowell JK
J Biol Chem; 2019 Nov; 294(48):18122-18130. PubMed ID: 31628193
[TBL] [Abstract][Full Text] [Related]
52. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
[TBL] [Abstract][Full Text] [Related]
53. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
Tan L; Wang J; Tanizaki J; Huang Z; Aref AR; Rusan M; Zhu SJ; Zhang Y; Ercan D; Liao RG; Capelletti M; Zhou W; Hur W; Kim N; Sim T; Gaudet S; Barbie DA; Yeh JR; Yun CH; Hammerman PS; Mohammadi M; Jänne PA; Gray NS
Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4869-77. PubMed ID: 25349422
[TBL] [Abstract][Full Text] [Related]
54. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
55. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.
Qian XJ; Li YT; Yu Y; Yang F; Deng R; Ji J; Jiao L; Li X; Wu RY; Chen WD; Feng GK; Zhu XF
Oncotarget; 2015 Mar; 6(7):5134-46. PubMed ID: 25762617
[TBL] [Abstract][Full Text] [Related]
57. Theoretical studies on FGFR isoform selectivity of FGFR1/FGFR4 inhibitors by molecular dynamics simulations and free energy calculations.
Fu W; Chen L; Wang Z; Kang Y; Wu C; Xia Q; Liu Z; Zhou J; Liang G; Cai Y
Phys Chem Chem Phys; 2017 Feb; 19(5):3649-3659. PubMed ID: 28094372
[TBL] [Abstract][Full Text] [Related]
58. Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines.
Kostopoulou ON; Holzhauser S; Lange BKA; Ohmayer A; Andonova T; Bersani C; Wickström M; Dalianis T
Int J Oncol; 2019 Dec; 55(6):1372-1384. PubMed ID: 31638167
[TBL] [Abstract][Full Text] [Related]
59. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ
Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
[TBL] [Abstract][Full Text] [Related]
60. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]